| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 03/10/2004 | CN1480211A Usage of gene NMESI related to esophageal carcinoma and encoded polypeptide |
| 03/09/2004 | US6703493 Ob (obesity) polypeptides possess an ability to participate in the control of mammalian body weight; use in detection, monitoring, screening, and diagnosis of modulators of weight control; use in treatment/regulation of obesity in mammals |
| 03/09/2004 | US6703486 Peripheral nervous system specific sodium channels |
| 03/09/2004 | US6703375 Molecular chemotherapy enhancement of radiotherapy |
| 03/09/2004 | US6703237 Recombinant adeno-associated virus (raav) vector comprising a heterologous sequence and heparin; for gene therapy |
| 03/09/2004 | US6703231 gM-negative EHV-mutants |
| 03/09/2004 | US6703215 Detecting preferential enzyme inhibitor; obtain substrate, incubate with enzyme mixture, expose to enzyme inhibitor, monitor for decrease in enzymatic activity |
| 03/09/2004 | US6703023 Circovirus sequences associated with piglet weight loss disease (PWD) |
| 03/09/2004 | US6703017 Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
| 03/04/2004 | WO2004019036A2 Method for identifying substances |
| 03/04/2004 | WO2004018999A2 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 03/04/2004 | WO2004018712A1 OLIGONUCLEOTIDE TAGGED NUCLEOSIDE TRIPHOSPHATES (OTNTPs) FOR GENETIC ANALYSIS |
| 03/04/2004 | WO2004018709A2 Single nucleotide polymorphisms predicting adverse drug reactions and drug efficacy in cardiovascular disease |
| 03/04/2004 | WO2004018697A2 Protease resistant ti-growth hormone releasing hormone |
| 03/04/2004 | WO2004018689A1 Anti-neoplastic viruses |
| 03/04/2004 | WO2004018686A1 Caged tetracycline (derivatives), their generation, and their use for photoactivated gene expression |
| 03/04/2004 | WO2004018684A2 T-cell epitopes in staphylococcal enterotoxin b |
| 03/04/2004 | WO2004018683A1 Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine |
| 03/04/2004 | WO2004018678A1 Preventives/remedies for cancer |
| 03/04/2004 | WO2004018648A2 Methods for treating patients and identifying therapeutics |
| 03/04/2004 | WO2004018630A2 Recombinant double-stranded rna phages and uses thereof |
| 03/04/2004 | WO2004018627A2 Methods for propagating adenovirus and virus produced thereby |
| 03/04/2004 | WO2004018512A2 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications |
| 03/04/2004 | WO2004018506A2 Inducible alphaviral/orip based gene expression system |
| 03/04/2004 | WO2004018502A1 Compounds binding to p-selectin |
| 03/04/2004 | WO2004018010A2 Methods of drug delivery using sulphated chitinous polymers |
| 03/04/2004 | WO2004017995A1 Preventive and/or therapeutic drugs for itch |
| 03/04/2004 | WO2004017945A1 Nanoparticles for dna administration to a target organ |
| 03/04/2004 | WO2004017909A2 Methods of reducing ischemic injury |
| 03/04/2004 | WO2004017727A1 A method of treatment and prophylaxis |
| 03/04/2004 | WO2004001020A3 Methods and means to promote gut absorption |
| 03/04/2004 | WO2003106636A3 Novel methods for the delivery of polynucleotides to cells |
| 03/04/2004 | WO2003097871A8 Marker molecules associated with lung tumors |
| 03/04/2004 | WO2003083485A3 Protein for use in hypoxia related conditions |
| 03/04/2004 | WO2003083089A3 Tolerogenic antigen-presenting cells |
| 03/04/2004 | WO2003083052A3 Method of using anti-apoptotic factors in gene expression |
| 03/04/2004 | WO2003075888A3 Materials containing multiple layers of vesicles |
| 03/04/2004 | WO2003074561A8 A method for treating allergic disease and asthma by recombinant adenovirus-and adeno-associated virus-mediated ifn-ϝ gene |
| 03/04/2004 | WO2003070941A3 Method for the identification of tissue-specific regulatory sequences |
| 03/04/2004 | WO2003068912A3 PSEUDOMONAS SYRINGAE HARPINS, HopPtoP AND HopPmaHPTO, AND THEIR USES |
| 03/04/2004 | WO2003065871A3 Methods and compositions for treating hematological disorders |
| 03/04/2004 | WO2003062372A3 Nanoparticle assembled hollow spheres |
| 03/04/2004 | WO2003055980A3 Il-17 like molecules and uses thereof |
| 03/04/2004 | WO2003050311A3 Methods and compositions for diagnosing and treating hypotrichosis simplex |
| 03/04/2004 | WO2003050300A3 Diagnosis and treatment of cancer |
| 03/04/2004 | WO2003050254A3 Novel chimeric tnf ligands |
| 03/04/2004 | WO2003043574A3 Pharmaceutical compositions in particulate form |
| 03/04/2004 | WO2003039566A3 Methods of treatment in situ in the lungs of mammals |
| 03/04/2004 | WO2003027271A3 Regulation of adenovirus dna packaging by iptg |
| 03/04/2004 | WO2003025189A3 A packaging complementation cell-line for sv-40 vectors |
| 03/04/2004 | WO2003005961A3 A controlled release biodegradable gel matrix |
| 03/04/2004 | WO2003000846A3 A novel g protein-coupled receptor, gave 3 |
| 03/04/2004 | WO2002100900A3 Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof |
| 03/04/2004 | WO2002083075A3 Akt and regulation of ra synovial fibroblast apoptosis |
| 03/04/2004 | WO2002082091A3 Method for identification of proteins from intracellular bacteria |
| 03/04/2004 | WO2002044424A9 Compositions, methods, apparatus and products comprising a stathmin/oncoprotein 18 sequence for detecting and treating cancer |
| 03/04/2004 | WO2002036780A8 Stearoyl-coa desaturase gene promoter |
| 03/04/2004 | WO2002020762A8 Tnf receptor-like molecules and uses thereof |
| 03/04/2004 | WO2002020748A8 Host cells for packing a recombinant adeno-associated virus (raav), method for the production and use thereof |
| 03/04/2004 | WO2002014352A9 Therapeutic compounds for ovarian cancer |
| 03/04/2004 | WO2002012502A9 Anti-tnf antibodies, compositions, methods and uses |
| 03/04/2004 | US20040044193 C. albicans tec1 gene (catec1) and the coded tecip protein |
| 03/04/2004 | US20040043958 Glucocorticoid enhancement of gene expression |
| 03/04/2004 | US20040043939 Peptide-based gemini compounds |
| 03/04/2004 | US20040043932 Leptin-related peptides |
| 03/04/2004 | US20040043929 Novel proteins and nucleic acids encoding same |
| 03/04/2004 | US20040043926 Comprises polypeptides for diagnosing, treating and preventing cardiomyopathy, atherosclerosis and cancer |
| 03/04/2004 | US20040043489 Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
| 03/04/2004 | US20040043487 Generating trangenic embryonic stem cells using vector insertional mutagenesis and nuclear transplantation |
| 03/04/2004 | US20040043454 Growth arrest homeobox gene |
| 03/04/2004 | US20040043411 DSP-11 dual-specificity phosphatase |
| 03/04/2004 | US20040043402 Interferon-alpha induced gene |
| 03/04/2004 | US20040043379 Methods and probe-immobilized substrates for obtaining information regarding responsiveness to a treatment of a disease |
| 03/04/2004 | US20040043079 Microencapsulated materials and method of making same |
| 03/04/2004 | US20040043063 In situ transfection; gene therapy; protein in liposome capsules |
| 03/04/2004 | US20040043024 Genetic engineering; isolation nucleic acids binded to heparin |
| 03/04/2004 | US20040043021 Asthma therapy, diagnosis |
| 03/04/2004 | US20040043010 Delivery of bioactive compounds to an organism |
| 03/04/2004 | US20040043008 Dissociation muscle tissues; culturing; accumulation |
| 03/04/2004 | US20040043007 Transfection system |
| 03/04/2004 | US20040043003 Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
| 03/04/2004 | US20040043000 Method of modulating fertility in animals |
| 03/04/2004 | CA2536254A1 Recombinant double-stranded rna phages and uses thereof |
| 03/04/2004 | CA2496781A1 Methods for treating patients and identifying therapeutics |
| 03/04/2004 | CA2496485A1 Use of an anti-g-csf or anti-g -csfr antibody or a soluble g- csfr for the treatment or prophylaxis of arthritis |
| 03/04/2004 | CA2496464A1 Agent for prevention and/or treatment of itching |
| 03/04/2004 | CA2496376A1 Methods of drug delivery using sulphated chitinous polymers |
| 03/04/2004 | CA2496272A1 Integrin b6 markers for compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer |
| 03/04/2004 | CA2496268A1 Oligonucleotide tagged nucleoside triphosphates (otntps) for genetic analysis |
| 03/04/2004 | CA2496242A1 T-cell epitopes in staphylococcal enterotoxin b |
| 03/04/2004 | CA2496236A1 Preventives/remedies for cancer |
| 03/04/2004 | CA2495546A1 Methods for propagating adenovirus and virus produced thereby |
| 03/04/2004 | CA2493471A1 Compounds binding to p-selectin |
| 03/04/2004 | CA2492807A1 Nanoparticles for dna administration to a target organ |
| 03/03/2004 | EP1394274A2 Methods of testing for bronchial asthma or chronic obstructive pulmonary disease |
| 03/03/2004 | EP1394267A1 Single nucleotide polymorphisms predictive for cardiovascular disease, adverse drug reactions, and drug efficacy |
| 03/03/2004 | EP1394258A1 Non-human herpesviruses as vectors |
| 03/03/2004 | EP1394255A2 NANBV diagnostics and vaccines |
| 03/03/2004 | EP1393776A1 Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| 03/03/2004 | EP1392867A2 Antisense modulation of ptp1b expression |